Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2012 1
2013 1
2016 1
2018 3
2019 1
2020 3
2021 9
2022 7
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Results by year

Filters applied: . Clear all
Page 1
CAR-T cell therapy and infection: a review.
Bupha-Intr O, Haeusler G, Chee L, Thursky K, Slavin M, Teh B. Bupha-Intr O, et al. Among authors: chee l. Expert Rev Anti Infect Ther. 2021 Jun;19(6):749-758. doi: 10.1080/14787210.2021.1855143. Epub 2020 Dec 31. Expert Rev Anti Infect Ther. 2021. PMID: 33249873 Review.
A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.
Réa D, Mauro MJ, Boquimpani C, Minami Y, Lomaia E, Voloshin S, Turkina A, Kim DW, Apperley JF, Abdo A, Fogliatto LM, Kim DDH, le Coutre P, Saussele S, Annunziata M, Hughes TP, Chaudhri N, Sasaki K, Chee L, García-Gutiérrez V, Cortes JE, Aimone P, Allepuz A, Quenet S, Bédoucha V, Hochhaus A. Réa D, et al. Among authors: chee l. Blood. 2021 Nov 25;138(21):2031-2041. doi: 10.1182/blood.2020009984. Blood. 2021. PMID: 34407542 Free PMC article. Clinical Trial.
Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL.
Hochhaus A, Réa D, Boquimpani C, Minami Y, Cortes JE, Hughes TP, Apperley JF, Lomaia E, Voloshin S, Turkina A, Kim DW, Abdo A, Fogliatto LM, le Coutre P, Sasaki K, Kim DDH, Saussele S, Annunziata M, Chaudhri N, Chee L, García-Gutiérrez V, Kapoor S, Allepuz A, Quenet S, Bédoucha V, Mauro MJ. Hochhaus A, et al. Among authors: chee l. Leukemia. 2023 Mar;37(3):617-626. doi: 10.1038/s41375-023-01829-9. Epub 2023 Jan 30. Leukemia. 2023. PMID: 36717654 Free PMC article. Clinical Trial.
Myeloid somatic mutation panel testing in myeloproliferative neoplasms.
Ross DM, Thomson C, Hamad N, Lane SW, Manos K, Grigg AP, Guo B, Erber WN, Scott A, Viiala N, Chee L, Latimer M, Tate C, Grove C, Perkins AC, Blombery P. Ross DM, et al. Among authors: chee l. Pathology. 2021 Apr;53(3):339-348. doi: 10.1016/j.pathol.2021.01.003. Epub 2021 Mar 3. Pathology. 2021. PMID: 33674147 Review.
Panel-based gene testing in myelodysplastic/myeloproliferative neoplasm overlap syndromes: Australasian Leukaemia and Lymphoma Group (ALLG) consensus statement.
Enjeti AK, Agarwal R, Blombery P, Chee L, Chua CC, Grigg A, Hamad N, Iland H, Lane S, Perkins A, Singhal D, Tate C, Tiong IS, Ross DM. Enjeti AK, et al. Among authors: chee l. Pathology. 2022 Jun;54(4):389-398. doi: 10.1016/j.pathol.2022.03.002. Epub 2022 Apr 20. Pathology. 2022. PMID: 35461716 Free article. Review.
Robust SARS-CoV-2 T cell responses with common TCRαβ motifs toward COVID-19 vaccines in patients with hematological malignancy impacting B cells.
Nguyen THO, Rowntree LC, Allen LF, Chua BY, Kedzierski L, Lim C, Lasica M, Tennakoon GS, Saunders NR, Crane M, Chee L, Seymour JF, Anderson MA, Whitechurch A, Clemens EB, Zhang W, Chang SY, Habel JR, Jia X, McQuilten HA, Minervina AA, Pogorelyy MV, Chaurasia P, Petersen J, Menon T, Hensen L, Neil JA, Mordant FL, Tan HX, Cabug AF, Wheatley AK, Kent SJ, Subbarao K, Karapanagiotidis T, Huang H, Vo LK, Cain NL, Nicholson S, Krammer F, Gibney G, James F, Trevillyan JM, Trubiano JA, Mitchell J, Christensen B, Bond KA, Williamson DA, Rossjohn J, Crawford JC, Thomas PG, Thursky KA, Slavin MA, Tam CS, Teh BW, Kedzierska K. Nguyen THO, et al. Among authors: chee l. Cell Rep Med. 2023 Apr 18;4(4):101017. doi: 10.1016/j.xcrm.2023.101017. Epub 2023 Mar 27. Cell Rep Med. 2023. PMID: 37030296 Free PMC article.
Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT.
Mehta RS, Holtan SG, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel DR, Alousi AM, Pidala J, Abdel-Azim H, Agrawal V, Ahmed I, Al-Homsi AS, Aljurf M, Antin JH, Askar M, Auletta JJ, Bhatt VR, Chee L, Chhabra S, Daly A, DeFilipp Z, Gajewski J, Gale RP, Gergis U, Hematti P, Hildebrandt GC, Hogan WJ, Inamoto Y, Martino R, Majhail NS, Marks DI, Nishihori T, Olsson RF, Pawarode A, Diaz MA, Prestidge T, Rangarajan HG, Ringden O, Saad A, Savani BN, Schoemans H, Seo S, Schultz KR, Solh M, Spitzer T, Storek J, Teshima T, Verdonck LF, Wirk B, Yared JA, Cahn JY, Weisdorf DJ. Mehta RS, et al. Among authors: chee l. J Clin Oncol. 2020 Jun 20;38(18):2062-2076. doi: 10.1200/JCO.19.00396. Epub 2020 May 4. J Clin Oncol. 2020. PMID: 32364845 Free PMC article.
29 results